ESTRO 2024 - Abstract Book

S5376

Radiobiology - Tumour biology

ESTRO 2024

Results:

We have designed boronated glucose transporter targeting molecules and have evaluated their uptake in vitro and in vivo using relevant cell lines. These molecules have good solubility and cellular uptake and, under the normoxia conditions in vitro, they can deliver 2-3 times more boron across multiple cell lines than can be achieved with L-BPA. We anticipate that these compounds have the potential to be applied to treating cancers that are glucose transporter rich or, conversely, have low LAT1 expression to ultimately expand upon traditional indications where BNCT is currently showing promise.

Conclusion:

We will present early in vitro and in vivo data, as well as synthesis pathways, for these compounds.

Keywords: BNCT, PDAC, GLUT1

1513

Mini-Oral

Homologous recombination promotes mitotic death, suppressing innate immune response to ablative RT

Harriet Gee 1,2 , Radek Szmyd 3 , Sienna Casolin 3 , Lucy French 3 , Christopher Nelson 4 , Lea Cavalli 3 , Anna Manjon 3 , Han Shen 5 , Eric Hau 6,2 , Tony Cesare 3,2 1 Westmead Hospital, Radiation Oncology, Sydney, Australia. 2 University of Sydney, Medicine, Sydney, Australia. 3 Childrens Medical Research Institute, Genome Integrity, Sydney, Australia. 4 Childrens Medical Research Institute, Telomere Length Regulation Unit, Sydney, Australia. 5 University of Sydney, Westmead Institute for Medical Research, Sydney, Australia. 6 Blacktown Hospital, Radiation Oncology, Sydney, Australia

Purpose/Objective:

Ablative Dose Radiotherapy (ART) is increasingly used worldwide, both as SABR/SBRT for early stage NSCLC or oligometastatic NSCLC, and as SRS for control of brain metastases. ART improves local control over conventionally fractionated radiotherapy, and emerging clinical data suggest synergy with immunotherapy. However, molecular mechanisms of cell death after ART remain almost unknown, hampering design of optimal ART dose and sequence.

Material/Methods:

A range of cell lines including immortalised normal and cancer cell lines were subjected to single fractions of radiation ranging from 2-20Gy in vitro. Outcomes were measured using long-duration live cell imaging, clonogenic assays, and